Your browser doesn't support javascript.
loading
Assessing the Effect of Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) on Outcomes in Patients With Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.
Nall, Scott; Rawat, Anurag; Gill, Fahad Shaukat; Saleem, Rushna; Saeed, Simran; Ahmed, Saeed; Wei, Calvin R; Allahwala, Danish.
Afiliación
  • Nall S; Medicine, Central Michigan University College of Medicine, Saginaw, USA.
  • Rawat A; Interventional Cardiology, Himalayan Institute of Medical Sciences, Dehradun, IND.
  • Gill FS; Medicine, Shalamar Medical and Dental College, Lahore, PAK.
  • Saleem R; Medicine, Rawalpindi Medical University, Rawalpindi, PAK.
  • Saeed S; Allied Health, University of Lahore, Lahore, PAK.
  • Ahmed S; Cardiology, Mohtarma Benazir Bhutto Shaheed Medical College, Mirpur, PAK.
  • Wei CR; Research and Development, Shing Huei Group, Taipei, TWN.
  • Allahwala D; Nephrology, Fatima Memorial Hospital, Karachi, PAK.
Cureus ; 16(6): e62978, 2024 Jun.
Article en En | MEDLINE | ID: mdl-39050303
ABSTRACT
After acute myocardial infarction, patients are at increased risk for adverse outcomes, including heart failure and death. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown promising cardiovascular benefits, but their efficacy in patients after myocardial infarction is not well established. This study aimed to evaluate the efficacy of SGLT2i in preventing cardiovascular outcomes in patients after myocardial infarction through a systematic review and meta-analysis. We conducted a comprehensive literature search of PubMed, Cochrane, EMBASE, and Web of Science for randomized controlled trials (RCTs) and retrospective and prospective studies evaluating SGLT2i in patients after myocardial infarction. The primary outcomes were major adverse cardiovascular events (MACEs) and all-cause mortality. Secondary outcomes included cardiovascular mortality, recurrent myocardial infarction, revascularization, and rehospitalization. Data were pooled using a random-effects model, and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. The meta-analysis included eight studies (three RCTs and five observational studies) with a follow-up duration ranging from 4 to 24 months. SGLT2i were associated with a significantly lower risk of MACE (RR 0.71, 95% CI 0.52-0.97, p = 0.03) and rehospitalization (RR 0.64, 95% CI 0.51-0.82, p<0.01) compared to controls. Although not statistically significant, the risk of all-cause mortality (RR 0.79, 95% CI 0.53-1.18, p = 0.25) and cardiovascular mortality was lower in the SGLT2i group. This meta-analysis suggests that SGLT2i may improve cardiovascular outcomes in patients after myocardial infarction, particularly by reducing the risk of MACEs and rehospitalization. However, larger trials with high-risk populations are needed to confirm these findings and elucidate the underlying mechanisms.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos